StreetInsider.com News Articles

Form 4 Immunovant, Inc. For: Aug 28 Filed by: Pande Atul

Fri, 28 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260828/26998433.html

Form 4 Immunovant, Inc. For: Aug 28 Filed by: Pande Atul

Fri, 28 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260828/26998433.html

Immunovant (IMVT) Reiterated at Overweight by Cantor Fitzgerald on Model Update

Tue, 25 Aug 2026 07:40:47 -0400

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Immunovant (NASDAQ: IMVT).

The analyst commented, "We are updating our model for operating expenses following FY1Q earnings. There were no other material changes from the quarter."

For an analyst ratings summary and ratings history on Immunovant click here. For more ratings news on Immunovant click here.

Shares of Immunovant closed at $43.32 yesterday.

Form 4 Immunovant, Inc. For: Aug 20 Filed by: Gloria Melanie

Fri, 21 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260821/26961321.html

Form 4 Immunovant, Inc. For: Aug 20 Filed by: Gloria Melanie

Fri, 21 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260821/26961321.html

Form SCHEDULE 13G/A Immunovant, Inc. Filed by: Deep Track Capital, LP

Fri, 14 Aug 2026 08:27:00 -0400

si-local-file:///var/storage/secattach/20260814/26925068.html

Form SCHEDULE 13G/A Immunovant, Inc. Filed by: Deep Track Capital, LP

Fri, 14 Aug 2026 08:27:00 -0400

si-local-file:///var/storage/secattach/20260814/26925068.html

Immunovant posts $153M net loss as R&D spending climbs in fiscal Q1

Thu, 06 Aug 2026 09:58:33 -0400

Immunovant (Nasdaq: IMVT) reported a net loss of $153.2 million, or $0.75 per share, for its fiscal first quarter ended June 30, 2026, compared with a net loss of $120.6 million, or $0.71 per share, in the same period a year earlier, according to a company press release.

Research and development expenses rose to $142.6 million from $101.2 million in the prior-year quarter, driven by clinical trial activity for IMVT-1402, including contract manufacturing costs, partially offset by reduced spending as the company winds down its batoclimab program. General and administrative expenses fell to $17.7 million from $26.0 million, reflecting lower personnel,

Immunovant posts $153M net loss as R&D spending climbs in fiscal Q1

Thu, 06 Aug 2026 09:58:33 -0400

Immunovant (IMVT) PT Raised to $57 at Stifel

Thu, 06 Aug 2026 09:50:07 -0400

Stifel analyst Alex Thompson raised the price target on Immunovant (NASDAQ: IMVT) to $57.00 (from $49.00) while maintaining a Buy rating.

Immunovant, Inc. (IMVT) Misses Q1 EPS by 15c

Thu, 06 Aug 2026 07:42:31 -0400

Immunovant, Inc. (NASDAQ: IMVT) reported Q1 EPS of ($0.75), $0.15 worse than the analyst estimate of ($0.60).

For earnings history and earnings-related data on Immunovant, Inc. (IMVT) click here.

Form 10-Q Immunovant, Inc. For: Jun 30

Thu, 06 Aug 2026 07:29:00 -0400

si-local-file:///var/storage/secattach/20260806/26878766.html

Form 10-Q Immunovant, Inc. For: Jun 30

Thu, 06 Aug 2026 07:29:00 -0400

si-local-file:///var/storage/secattach/20260806/26878766.html

Form 8-K Immunovant, Inc. For: Aug 06

Thu, 06 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260806/26878659.html

Form 8-K Immunovant, Inc. For: Aug 06

Thu, 06 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260806/26878659.html

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026